IVIG Reduces Grade 2 Infections by 67 Percent in CLL
A study has found that intravenous immune globulin (IVIG) reduces grade 2 infections by 67 percent in patients with chronic lymphocytic leukemia.
Takeda’s TAK-881 SCIG Product Meets Primary and Secondary Endpoints in Phase II/III Clinical Trial
Takeda’s pivotal Phase II/III clinical trial of its investigational TAK-881K SCIG 20% with recombinant human hyaluronidase) in patients with primary immunodeficiency met its primary and secondary endpoints.
FDA Approves Expanded Label for ASCENIV for PI Patients 2 Years and Older
The U.S. Food and Drug Administration has approved ADMA Biologics’ supplemental biologics license application to expand the prescribing information to primary humoral immunodeficiency indication to pediatric patients 2 years of age and older.
New Bill Introduced to Ensure Dedicated Payment for IVIG in Skilled Nursing Facilities
U.S. Representatives Adrian Smith (R-NE-03) and Doris Matsui (D-CA-07) have introduced the PI Post Acute Access Act to expand access to lifesaving care for individuals with primary immunodeficiencies
IVIG Results in Improved Response Rate in Patients with Autoimmune Encephalitis
Intravenous immune globulin (IVIG) improved clinical response rates in patients with autoimmune encephalitis (AE) who had inadequate response to steroid pulse therapy.
New Assay to Accurately Measure FXI Levels During IVIG Therapy
GC Biopharma has developed a proprietary enzyme-linked immunoassay (ELISA) that effectively mitigates heterophilic antibody interference to precisely measure factor XI (FXI) levels.
IVIG Effective in Treating Infants with HDFN
A recent study has found intravenous immune globulin (IVIG) therapy in infants with hemolytic disease of the fetus and newborn (HDFN) found that it could be beneficial.
IVIG Plus IVMP Does Not Increase Remission Rates in CIDP Patients
According to a recent study, adding intravenous methylprednisolone to intravenous immune globulin induction therapy does not significantly increase remission rates among patients with chronic inflammatory demyelinating polyradiculoneuropathy.
GAMMAGARD LIQUID ERC Is Now Available in the U.S.
GAMMAGARD LIQUID ERC (immune globulin infusion [human]) with less than or equal to 2 µg/mL IgA in a 10% solution, by prescription, is now available in the U.S.
SARS-CoV-2 and COVID-19: Plasma Supply and IG Replacement Therapy to Protect Immunodeficient Patients
Can anti-SARS-CoV-2 antibodies in the plasma supply protect against COVID infection in
immunodeficient patients? Research suggests otherwise.